• Joseph B Franklin, Caroline Marra, Kaleab Z Abebe, Atul J Butte, Deborah J Cook, Laura Esserman, Lee A Fleisher, Cynthia I Grossman, Nancy E Kass, Harlan M Krumholz, Kathy Rowan, Amy P Abernethy, and JAMA Summit on Clinical Trials Participants.
• Verily Life Sciences, South San Francisco, California.
• JAMA. 2024 Aug 5.

ImportanceThe ways in which we access, acquire, and use data in clinical trials have evolved very little over time, resulting in a fragmented and inefficient system that limits the amount and quality of evidence that can be generated.ObservationsClinical trial design has advanced steadily over several decades. Yet the infrastructure for clinical trial data collection remains expensive and labor intensive and limits the amount of evidence that can be collected to inform whether and how interventions work for different patient populations. Meanwhile, there is increasing demand for evidence from randomized clinical trials to inform regulatory decisions, payment decisions, and clinical care. Although substantial public and industry investment in advancing electronic health record interoperability, data standardization, and the technology systems used for data capture have resulted in significant progress on various aspects of data generation, there is now a need to combine the results of these efforts and apply them more directly to the clinical trial data infrastructure.Conclusions And RelevanceWe describe a vision for a modernized infrastructure that is centered around 2 related concepts. First, allowing the collection and rigorous evaluation of multiple data sources and types and, second, enabling the possibility to reuse health data for multiple purposes. We address the need for multidisciplinary collaboration and suggest ways to measure progress toward this goal.

8 keywords...

hide…